General counsel Mark Nance joined Insys Therapeutics Inc. in October as the company was working toward settling civil and criminal allegations that it bribed doctors to prescribe one of its popular opioid drugs. But if Nance was part of the $225 million global settlement announced Wednesday, there was no outward sign of it.

Nance’s name was not on the five-year deferred prosecution agreement that Insys accepted, nor on the five-year corporate integrity agreement—which the government called an “unprecedented” deal. It includes a “conditional exclusion release” that allows the government to exclude the company from federal contracts, such as Medicare, if it materially breaches the terms.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]